UPDATE: Pacylex Raises US $3.9 Million To Advance New Cancer Therapy PCLX-001 Towards Clinical Trials
Summary
Pacylex previously raised approximately US $2 million in convertible note financings in 2018 and 2019 from a mix of US and Canadian angel investors. DavosPharma believes it is uniquely positioned to provide IND / NDA development support through its fully integrated translational turn-key approach that has enabled its pharmaceutical clients to achieve filings on a strict timeline. With biologists and chemists on staff, DavosPharma provides guidance and manufacturing capabilities for both small molecule (including cytotoxic and high potency) and biologics (antibodies, ADCs, protein and peptide therapeutics). Formulation experience includes IV, Oral, Sub Q, IP, Ocular, Dermal, Intranasal and Inhalation routes of administration. DavosPharma offers CMC, toxicology and clinical regulatory support for writing and execution of INDs and updates through NDA with the FDA.